-
Mashup Score: 11
The scaled-down version of H.R. 3 embodied in the new Democratic drug pricing agreement would be still be a significant advance for millions of patients struggling to afford their prescription drugs.
Source: www.healthaffairs.orgCategories: Latest Headlines, PayerTweet
-
Mashup Score: 8Mass General Brigham vetoes controversial Alzheimer's drug Aduhelm after internal review - 3 year(s) ago
The Massachusetts system’s decision not to provide Biogen’s Aduhelm to patients follows a review by its internal expert panel. It comes after other big-name providers and payers said they would not support the treatment earlier this summer.
Source: FierceHealthcareCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@MassGenBrigham vetoes controversial #Alzheimers drug Aduhelm after internal review | #drugpricing #pharma https://t.co/4zDNeUI1Y0
-
-
Mashup Score: 0
U.S. sales for the 20 top-selling drugs worldwide in 2020 was nearly double the amount the rest of the world paid for the same drugs, according to a report released Sept. 30 by consumer rights advocacy group Public Citizen.
Source: www.beckershospitalreview.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Americans pay more for 20 top drugs than rest of the world combined, study shows | #drugpricing #pharma https://t.co/C0glJgaESC
-
-
Mashup Score: 0Contentious report suggests safety net hospitals leveraging discounts to pocket strong gains from cancer drugs - 3 year(s) ago
A price transparency report from the Community Oncology Alliance suggests the charity hospitals are leveraging their discounts to pocket strong gains from cancer drugs. An industry group representing 340B hospitals took issue with their methodology and the implied use of those savings.
Source: FierceHealthcareCategories: Future of Medicine, Latest HeadlinesTweet-
Contentious report suggests safety net hospitals leveraging discounts to pocket strong gains from #cancer drugs | #drugpricing #pricetransparency https://t.co/4WFdcTBcvC
-
-
Mashup Score: 2Biden Drug Pricing Plan Seeks To Balance Access And Innovation | Health Affairs Blog - 3 year(s) ago
Both the new Biden administration drug pricing plan and the Trump Administration’s May 2018 blueprint identified the need to bolster competition. However, in practice the two reports diverge in identifying policy solutions on this topic.
Source: www.healthaffairs.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
In her new blog post, @RESachs of @WUSTL discusses how the Biden admin's new #DrugPricing plan and the Trump admin's 2018 blueprint both identified the need to bolster competition, but the two reports diverge in identifying policy solutions on this topic. https://t.co/iaP6j5SMN5
-
-
Mashup Score: 1Annual Report of the Executive Vice President 2020—2021 - 3 year(s) ago
Dear Colleagues, This was a year marked by uncertainty and upheaval, but even in the most trying of times, internal medicine stepped up and stood out for its leadership role and steady focus on prioritizing the welfare of …
Source: assets.acponline.orgCategories: Hospital-Based Medicine, Latest HeadlinesTweet-
ACP advocates for #InternalMedicine. Our 2020-21 Annual EVP Report features those efforts https://t.co/9UMjO85oHG. Including #COVID19 vaccination, masks in schools, #ACPVision4HealthCare, #DEI, physician payments, #telehealth, prescription #DrugPricing and more. @DarilynMoyer https://t.co/5q2xfY39Hn
-
-
Mashup Score: 1Pondering Prescription Drugs: Pricing Rx and Going Direct-to-Consumer - HealthPopuli.com - 3 year(s) ago
There is one health care public policy issue that unites U.S. voters across political party: that is the consumer-facing costs of prescription drugs. With the price of medicines in politicians’ and health citizens’ cross-hairs, the pharmaceutical and biotech industries have responded in many ways to the Rx pricing critiques from consumers (via, for example, Consumer Reports/Consumers Union and…
Source: HealthPopuli.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Drug utilization management ->$93 bn economic burden on patients, physicians, payers & #pharma cos @Health_Affairs models 4 UM stakeholders & UM costs for each: patients bear >$burden https://t.co/Wfc7cg8M1B #DrugPricing #DTC #Telehealth #Healthconsumers #retailhealth https://t.co/8cHBB2KkD4
-
-
Mashup Score: 1Biden directs Congress to give Medicare broad authority to negotiate for lower drug prices - 3 year(s) ago
Biden outlined a bold agenda to tackle drug prices, directing Congress to give Medicare wide authority to negotiate lower prices with drugmakers.
Source: FierceHealthcareCategories: Healthcare Professionals, Latest HeadlinesTweet-
#Biden directs #Congress to give #Medicare broad authority to negotiate for lower drug prices | #drugpricing #pharma https://t.co/w01jEzyKea
-
-
Mashup Score: 0
Senate Democrats on Aug. 9 released a $3. 5 trillion budget resolution they hope to pass by the end of this week.
Source: www.beckershospitalreview.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
#Senate Democrats unveil $3.5 trillion budget: 5 #healthcare takeaways | #medicaid #medicare #homehealth #aginginplace #seniorcare #drugpricing https://t.co/CF9fXxh5lH
-
-
Mashup Score: 0
What good is a drug therapy if patients can’t afford it?
Source: catalyst.nejm.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The convergence of patient and consumer is here to stay, says the CMO for @OptumRx, and the ability for providers and patients to judge a drug’s value is the way of the future: https://t.co/3DPv206q2s #drugpricing
-
In her new blog post, @RESachs of @WUSTL argues that the scaled-down version of H.R. 3 embodied in the new Democratic #DrugPricing agreement would be still be a significant advance for millions of patients struggling to afford their prescription drugs. https://t.co/0tSxtkyNjA